Neuroinflammation in prion diseases: Concepts and targets for therapeutic intervention

CNS and Neurological Disorders - Drug Targets

Volumn 8, Issue 5, 2009, Pages 329-341

  Riemer, Constanze ^a   Gültner, Sandra ^a   Heise, Ines ^a   Holtkamp, Nikola ^b   Baier, Michael ^a  

^a ROBERT KOCH INSTITUTE   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; CHEMOKINE; CURCUMIN; CYTOKINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; IBUPROFEN; NAPROXEN; NEUROPROTECTIVE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PRAVASTATIN; PRION PROTEIN; SIMVASTATIN; SMALL INTERFERING RNA; SQUALENE SYNTHASE INHIBITOR;

CYTOKINE RELEASE; CYTOTOXICITY; ENCEPHALITIS; GLIA CELL; GLIOSIS; HUMAN; NERVE CELL NECROSIS; NONHUMAN; PRION DISEASE; PROTEIN FOLDING; REVIEW; BRAIN; INFLAMMATION; METABOLISM; PATHOLOGY; PRION;

BRAIN; CHEMOKINES; CYTOKINES; INFLAMMATION; PRION DISEASES; PRIONS;

EID: 73949132603     PISSN: 18715273     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152709789542014     Document Type: Review

References (153)

1. Prusiner, S.B. Prions. Proc. Natl. Acad. Sci. USA, 1998, 95, 13363-13383.
2. Chesebro, B. Prion protein and the transmissible spongiform encephalopathy diseases. Neuron, 1999, 24, 503-506.
3. Rezaie, P.; Lantos, P.L. Microglia and the pathogenesis of spongiform encephalopathies. Brain Res. Brain Res. Rev., 2001, 35, 55-72.
4. Burwinkel, M.; Riemer, C.; Schwarz, A.; Schultz, J.; Neidhold, S.; Bamme, T.; Baier, M. Role of cytokines and chemokines in prion infections of the central nervous system. Int. J. Dev. Neurosci., 2004, 22, 497-505.
5. Lauren, J.; Gimbel, D.A.; Nygaard, H.B.; Gilbert, J.W.; Strittmatter, S.M. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature, 2009, 457, 1128-1132.
6. Cisse, M.; Mucke, L. Alzheimer's disease: a prion protein connection. Nature 2009, 457, 1090-1091.
7. Forloni, G.; Angeretti, N.; Chiesa, R.; Monzani, E.; Salmona, M.; Bugiani, O.; Tagliavini, F. Neurotoxicity of a prion protein fragment. Nature, 1993, 362, 543-546.
8. Chiesa, R.; Harris, D.A. Prion diseases: what is the neurotoxic molecule? Neurobiol. Dis., 2001, 8, 743-763.
9. Hetz, C.; Russelakis-Carneiro, M.; Maundrell, K.; Castilla, J.; Soto, C. Caspase-12 and endoplasmic reticulum stress mediate neurotoxicity of pathological prion protein. EMBO J., 2003, 22, 5435-5445.
10. Brown, D.R.; Kretzschmar, H.A. Microglia and prion disease: a review. Histol. Histopathol., 1997, 12, 883-892.
11. Giese, A.; Brown, D.R.; Groschup, M.H.; Feldmann, C.; Haist, I.; Kretzschmar, H.A. Role of microglia in neuronal cell death in prion disease. Brain Pathol., 1998, 8, 449-457.
12. Brown, D.R.; Herms, J.; Kretzschmar, H.A. Mouse cortical cells lacking cellular PrP survive in culture with a neurotoxic PrP fragment. Neuroreport, 1994, 5, 2057-2060.
13. Giese, A.; Groschup, M.H.; Hess, B.; Kretzschmar, H.A. Neuronal cell death in scrapie-infected mice is due to apoptosis. Brain Pathol., 1995, 5, 213-221.
14. Raeber, A.J.; Race, R.E.; Brandner, S.; Priola, S.A.; Sailer, A.; Bessen, R.A.; Mucke, L.; Manson, J.; Aguzzi, A.; Oldstone, M.B.; Weissmann, C.; Chesebro, B. Astrocyte-specific expression of hamster prion protein (PrP) renders PrP knockout mice susceptible to hamster scrapie. EMBO J., 1997, 16, 6057-6065.
15. Jeffrey, M.; Goodsir, C.M.; Race, R.E.; Chesebro, B. Scrapiespecific neuronal lesions are independent of neuronal PrP expression. Ann. Neurol., 2004, 55, 781-792.
16. Mallucci, G.; Dickinson, A.; Linehan, J.; Klohn, P.C.; Brandner, S.; Collinge, J. Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis. Science, 2003, 302, 871-874.
17. Mallucci, G.R.; White, M.D.; Farmer, M.; Dickinson, A.; Khatun, H.; Powell, A.D.; Brandner, S.; Jefferys, J.G.; Collinge, J. Targeting cellular prion protein reverses early cognitive deficits and neurophysiological dysfunction in prion-infected mice. Neuron, 2007, 53, 325-335.
18. Brown, A.R.; Webb, J.; Rebus, S.; Walker, R.; Williams, A.; Fazakerley, J.K. Inducible cytokine gene expression in the brain in the ME7/CV mouse model of scrapie is highly restricted, is at a strikingly low level relative to the degree of gliosis and occurs only late in disease. J. Gen. Virol., 2003, 84, 2605-2611.
19. Klein, M.A.; Frigg, R.; Flechsig, E.; Raeber, A.J.; Kalinke, U.; Bluethmann, H.; Bootz, F.; Suter, M.; Zinkernagel, R.M.; Aguzzi, A. A crucial role for B cells in neuroinvasive scrapie. Nature, 1997, 390, 687-690.
20. Lewicki, H.; Tishon, A.; Homann, D.; Mazarguil, H.; Laval, F.; Asensio, V.C.; Campbell, I.L.; DeArmond, S.; Coon, B.; Teng, C.; Gairin, J.E.; Oldstone, M.B. T cells infiltrate the brain in murine and human transmissible spongiform encephalopathies. J. Virol., 2003, 77, 3799-3808.
21. Williams, A.E.; Lawson, L.J.; Perry, V.H.; Fraser, H. Characterization of the microglial response in murine scrapie. Neuropathol. Appl. Neurobiol., 1994, 20, 47-55.
22. Williams, A.; Lucassen, P.J.; Ritchie, D.; Bruce, M. PrP deposition, microglial activation, and neuronal apoptosis in murine scrapie. Exp. Neurol., 1997, 144, 433-438.
23. Williams, A.; Van Dam, A.M.; Ritchie, D.; Eikelenboom, P.; Fraser, H. Immunocytochemical appearance of cytokines, prostaglandin E2 and lipocortin-1 in the CNS during the incubation period of murine scrapie correlates with progressive PrP accumulations. Brain Res., 1997, 754, 171-180.
24. Riemer, C.; Queck, I.; Simon, D.; Kurth, R.; Baier, M. Identification of upregulated genes in scrapie-infected brain tissue. J. Virol., 2000, 74, 10245-10248.
25. Meda, L.; Baron, P.; Scarlato, G. Glial activation in Alzheimer's disease: the role of Abeta and its associated proteins. Neurobiol. Aging, 2001, 22, 885-893.
26. Gonzalez-Scarano, F.; Baltuch, G. Microglia as mediators of inflammatory and degenerative diseases. Annu. Rev. Neurosci., 1999, 22, 219-240.
27. Streit, W.J.; Walter, S.A.; Pennell, N.A. Reactive microgliosis. Prog. Neurobiol., 1999, 7, 563-581.
28. Rogers, J.; Strohmeyer, R.; Kovelowski, C.J.; Li, R. Microglia and inflammatory mechanisms in the clearance of amyloid beta peptide. Glia, 2002, 40, 260-269.
29. Le, Y.; Gong, W.; Tiffany, H.L.; Tumanov, A.; Nedospasov, S.; Shen, W.; Dunlop, N.M.; Gao, J.L.; Murphy, P.M.; Oppenheim, J.J.; Wang, J.M. Amyloid (beta)42 activates a G-protein-coupled chemoattractant receptor, FPR-like-1. J. Neurosci., 2001, 21, RC123.
30. Le, Y.; Yazawa, H.; Gong, W.; Yu, Z.; Ferrans, V.J.; Murphy, P.M.; Wang, J.M. The neurotoxic prion peptide fragment PrP(106-126) is a chemotactic agonist for the G protein-coupled receptor formyl peptide receptor-like 1. J. Immunol., 2001, 166, 1448-1451.
31. Brandenburg, L.O.; Koch, T.; Sievers, J.; Lucius, R. Internalization of PrP106-126 by the formyl-peptide-receptor-like-1 in glial cells. J. Neurochem., 2007, 101, 718-728.
32. Spinner, D.S.; Cho, I.S.; Park, S.Y.; Kim, J.I.; Meeker, H.C.; Ye, X.; Lafauci, G.; Kerr, D.J.; Flory, M.J.; Kim, B.S.; Kascsak, R.B.; Wisniewski, T.; Levis, W.R.; Schuller-Levis, G.B.; Carp, R.I.; Park, E.; Kascsak, R.J. Accelerated prion disease pathogenesis in Toll-like receptor 4 signaling-mutant mice. J. Virol., 2008, 82, 10701-10708.
33. Prinz, M.; Heikenwalder, M.; Schwarz, P.; Takeda, K.; Akira, S.; Aguzzi, A. Prion pathogenesis in the absence of Toll-like receptor signalling. EMBO Rep., 2003, 4, 195-199.
34. Mohan, J.; Hopkins, J.; Mabbott, N.A. Skin-derived dendritic cells acquire and degrade the scrapie agent following in vitro exposure. Immunology, 2005, 116, 122-133.
35. Gilch, S.; Schmitz, F.; Aguib, Y.; Kehler, C.; Bulow, S.; Bauer, S.; Kremmer, E.; Schatzl, H.M. CpG and LPS can interfere negatively with prion clearance in macrophage and microglial cells. FEBS J., 2007, 274, 5834-5844.
36. Combs, C.K.; Johnson, D.E.; Cannady, S.B.; Lehman, T.M.; Landreth, G.E. Identification of microglial signal transduction pathways mediating a neurotoxic response to amyloidogenic fragments of beta-amyloid and prion proteins. J. Neurosci., 1999, 19, 928-939.
37. Santiago-Garcia, J.; Mas-Oliva, J.; Innerarity, T.L.; Pitas, R.E. Secreted forms of the amyloid-beta precursor protein are ligands for the class A scavenger receptor. J. Biol. Chem., 2001, 276, 30655-30661.
38. Husemann, J.; Loike, J.D.; Anankov, R.; Febbraio, M.; Silverstein, S.C. Scavenger receptors in neurobiology and neuropathology: their role on microglia and other cells of the nervous system. Glia, 2002, 40, 195-205.
39. Husemann, J.; Loike, J.D.; Kodama, T.; Silverstein, S.C. Scavenger receptor class B type I (SR-BI) mediates adhesion of neonatal murine microglia to fibrillar beta-amyloid. J. Neuroimmunol., 2001, 114, 142-150.
40. El Khoury, J.B.; Moore, K.J.; Means, T.K.; Leung, J.; Terada, K.; Toft, M.; Freeman, M.W.; Luster, A.D. CD36 mediates the innate host response to beta-amyloid. J. Exp. Med., 2003, 197, 1657-1666.
41. Yan, S.D.; Chen, X.; Fu, J.; Chen, M.; Zhu, H.; Roher, A.; Slattery, T.; Zhao, L.; Nagashima, M.; Morser, J.; Migheli, A.; Nawroth, P.; Stern, D.; Schmidt, A.M. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature, 1996, 382, 685-691.
42. Deane, R.; Du Yan, S.; Submamaryan, R.K.; LaRue, B.; Jovanovic, S.; Hogg, E.; Welch, D.; Manness, L.; Lin, C.; Yu, J.; Zhu, H.; Ghiso, J.; Frangione, B.; Stern, A.; Schmidt, A.M.; Armstrong, D.L.; Arnold, B.; Liliensiek, B.; Nawroth, P.; Hofman, F.; Kindy, M.; Stern, D.; Zlokovic, B. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat. Med., 2003, 9, 907-913.
43. Alarcon, R.; Fuenzalida, C.; Santibanez, M.; von Bernhardi, R. Expression of scavenger receptors in glial cells: comparing the adhesion of astrocytes and microglia from neonatal rats to surface-bound beta-amyloid. J. Biol. Chem., 2005, 280, 30406-30415.
44. Fassbender, K.; Walter, S.; Kuhl, S.; Landmann, R.; Ishii, K.; Bertsch, T.; Stalder, A.K.; Muehlhauser, F.; Liu, Y.; Ulmer, A.J.; Rivest, S.; Lentschat, A.; Gulbins, E.; Jucker, M.; Staufenbiel, M.; Brechtel, K.; Walter, J.; Multhaup, G.; Penke, B.; Adachi, Y.; Hartmann, T.; Beyreuther, K. The LPS receptor (CD14) links innate immunity with Alzheimer's disease. FASEB J., 2004, 18, 203-205.
45. Wyss-Coray, T.; Loike, J.D.; Brionne, T.C.; Lu, E.; Anankov, R.; Yan, F.; Silverstein, S.C.; Husemann, J. Adult mouse astrocytes degrade amyloid-beta in vitro and in situ. Nat. Med., 2003, 9, 453-457.
46. Flores-Langarica, A.; Sebti, Y.; Mitchell, D.A.; Sim, R.B.; MacPherson, G.G. Scrapie pathogenesis: the role of complement C1q in scrapie agent uptake by conventional dendritic cells. J. Immunol., 2009, 182, 1305-1313.
47. Bonifati, D.M.; Kishore, U. Role of complement in neurodegeneration and neuroinflammation. Mol. Immunol., 2007, 44, 999-1010.
48. Greil, C.S.; Vorberg, I.M.; Ward, A.E.; Meade-White, K.D.; Harris, D.A.; Priola, S.A. Acute cellular uptake of abnormal prion protein is cell type and scrapie-strain independent. Virology, 2008, 379, 284-293.
49. Kopacek, J.; Sakaguchi, S.; Shigematsu, K.; Nishida, N.; Atarashi, R.; Nakaoke, R.; Moriuchi, R.; Niwa, M.; Katamine, S. Upregulation of the genes encoding lysosomal hydrolases, a perforin-like protein, and peroxidases in the brains of mice affected with an experimental prion disease. J. Virol., 2000, 74, 411-417.
50. Duguid, J.R.; Rohwer, R.G.; Seed, B. Isolation of cDNAs of scrapie-modulated RNAs by subtractive hybridization of a cDNA library. Proc. Natl. Acad. Sci. USA, 1988, 85, 5738-5742.
51. Dandoy-Dron, F.; Guillo, F.; Benboudjema, L.; Deslys, J.P.; Lasmezas, C.; Dormont, D.; Tovey, M.G.; Dron, M. Gene expression in scrapie. Cloning of a new scrapie-responsive gene and the identification of increased levels of seven other mRNA transcripts. J. Biol. Chem., 1998, 273, 7691-7697.
52. Booth, S.; Bowman, C.; Baumgartner, R.; Dolenko, B.; Sorensen, G.; Robertson, C.; Coulthart, M.; Phillipson, C.; Somorjai, R. Molecular classification of scrapie strains in mice using gene expression profiling. Biochem. Biophys. Res. Commun., 2004, 325, 1339-1345.
53. Booth, S.; Bowman, C.; Baumgartner, R.; Sorensen, G.; Robertson, C.; Coulthart, M.; Phillipson, C.; Somorjai, R.L. Identification of central nervous system genes involved in the host response to the scrapie agent during preclinical and clinical infection. J. Gen. Virol., 2004, 85, 3459-3471.
54. Sorensen, G.; Medina, S.; Parchaliuk, D.; Phillipson, C.; Robertson, C.; Booth, S.A. Comprehensive transcriptional profiling of prion infection in mouse models reveals networks of responsive genes. BMC Genomics, 2008, 9, 114.
55. Xiang, W.; Windl, O.; Wunsch, G.; Dugas, M.; Kohlmann, A.; Dierkes, N.; Westner, I.M.; Kretzschmar, H.A. Identification of differentially expressed genes in scrapie-infected mouse brains by using global gene expression technology. J. Virol., 2004, 78, 11051-11060.
56. Riemer, C.; Neidhold, S.; Burwinkel, M.; Schwarz, A.; Schultz, J.; Kratzschmar, J.; Monning, U.; Baier, M. Gene expression profiling of scrapie-infected brain tissue. Biochem. Biophys. Res. Commun., 2004, 323, 556-564.
57. Xiang, W.; Windl, O.; Westner, I.M.; Neumann, M.; Zerr, I.; Lederer, R.M.; Kretzschmar, H.A. Cerebral gene expression profiles in sporadic Creutzfeldt-Jakob disease. Ann. Neurol., 2005, 58, 242-257.
58. Skinner, P.J.; Abbassi, H.;Chesebro, B.; Race, R.E.; Reilly, C.; Haase, A.T. Gene expression alterations in brains of mice infected with three strains of scrapie. BMC Genomics, 2006, 7, 114.
59. Brown, A.R.; Webb, J.; Rebus, S.; Williams, A.; Fazakerley, J.K. Identification of up-regulated genes by array analysis in scrapie-infected mouse brains. Neuropathol. Appl. Neurobiol., 2004, 30, 555-567.
60. Brown, A.R.; Rebus, S.; McKimmie, C.S.; Robertson, K,; Williams, A.; Fazakerley, J.K. Gene expression profiling of the preclinical scrapie-infected hippocampus. Biochem. Biophys. Res. Commun., 2005, 334, 86-95.
61. Huang, J.; Kim, L.J.; Mealey, R.; Marsh, H.C., Jr.; Zhang, Y.; Tenner, A.J.; Connolly, E.S., Jr.; Pinsky, D.J. Neuronal protection in stroke by an sLex-glycosylated complement inhibitory protein. Science, 1999, 285, 595-599.
62. McGeer, P.L.; McGeer, E.G. The possible role of complement activation in Alzheimer disease. Trends Mol. Med., 2002, 8, 519-523.
63. Cai, H.; Griendling, K.K.; Harrison, D.G. The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases. Trends Pharmacol. Sci., 2003, 24, 471-478.
64. Mok, S.W.; Riemer, C.; Madela, K.; Hsu, D.K.; Liu, F.T.; Gultner, S.; Heise, I.; Baier, M. Role of galectin-3 in prion infections of the CNS. Biochem. Biophys. Res. Commun., 2007, 359, 672-678.
65. Nakanishi, H. Neuronal and microglial cathepsins in aging and age-related diseases. Ageing Res. Rev., 2003, 2, 367-381.
66. Mucke, L.; Yu, G.Q.; McConlogue, L.; Rockenstein, E.M.; Abraham, C.R.; Masliah, E. Astroglial expression of human alpha(1)-antichymotrypsin enhances alzheimer-like pathology in amyloid protein precursor transgenic mice. Am. J. Pathol., 2000, 157, 2003-2010.
67. Miele, G.; Seeger, H.; Marino, D.; Eberhard, R.; Heikenwalder, M.; Stoeck, K.; Basagni, M.; Knight, R.; Green, A.; Chianini, F.; Wuthrich, R.P.; Hock, C.; Zerr, I.; Aguzzi, A.; Urinary alpha1-antichymotrypsin: a biomarker of prion infection. PLoS One, 2008, 3, e3870.
68. Walsh, D.T.; Betmouni, S. Perry, V.H. Absence of detectable IL-1beta production in murine prion disease: a model of chronic neurodegeneration. J. Neuropathol. Exp. Neurol., 2001, 60, 173-182.
69. Baker, C.A.; Lu, Z.Y.; Zaitsev, I.; Manuelidis, L. Microglial activation varies in different models of Creutzfeldt-Jakob disease. J. Virol., 1999, 73, 5089-5097.
70. Tamguney, G.; Giles, K.; Glidden, D.V.; Lessard, P.; Wille, H.; Tremblay, P.; Groth, D.F.; Yehiely, F.; Korth, C.; Moore, R.C.; Tatzelt, J.; Rubinstein, E.; Boucheix, C.; Yang, X.; Stanley, P.; Lisanti, M.P.; Dwek, R.A.; Rudd, P.M.; Moskovitz, J.; Epstein, C.J.; Cruz, T.D.; Kuziel, W.A.; Maeda, N.; Sap, J.; Ashe, K.H.; Carlson, G.A.; Tesseur, I.; Wyss-Coray, T.; Mucke, L.; Weisgraber, K.H.; Mahley, R.W.; Cohen, F.E.; Prusiner, S.B. Genes contributing to prion pathogenesis. J. Gen. Virol., 2008, 89, 1777-1788.
71. Campbell, I.L.; Eddleston, M.; Kemper, P.; Oldstone, M.B.; Hobbs, M.V. Activation of cerebral cytokine gene expression and its correlation with onset of reactive astrocyte and acute-phase response gene expression in scrapie. J. Virol., 1994, 68, 2383-2387.
72. Allan, S.M.; Rothwell, N.J. Cytokines and acute neurodegeneration. Nat. Rev. Neurosci., 2001, 2, 734-744.
73. Cunningham, C.; Wilcockson, D.C.; Boche, D.; Perry, V.H. Comparison of inflammatory and acute-phase responses in the brain and peripheral organs of the ME7 model of prion disease. J. Virol., 2005, 79, 5174-5184.
74. Kercher, L.; Favara, C.; Striebel, J.F.; LaCasse, R.; Chesebro, B. Prion protein expression differences in microglia and astroglia influence scrapie-induced neurodegeneration in the retina and brain of transgenic mice. J. Virol., 2007, 81, 10340-10351.
75. Allan, S.M.; Rothwell, N.J. Inflammation in central nervous system injury. Philos. Trans. R. Soc. Lond. B. Biol. Sci., 2003, 358, 1669-1677.
76. Basu, A.; Krady, J.K.; O'Malley, M.; Styren, S.D.; DeKosky, S.T.; Levison, S.W. The type 1 interleukin-1 receptor is essential for the efficient activation of microglia and the induction of multiple proinflammatory mediators in response to brain injury. J. Neurosci., 2002, 22, 6071-6082.
77. Simi, A.; Tsakiri, N.; Wang, P.; Rothwell, N.J. Interleukin-1 and inflammatory neurodegeneration. Biochem. Soc. Trans., 2007, 35, 1122-1126.
78. Schultz, J.; Schwarz, A.; Neidhold, S.; Burwinkel, M.; Riemer, C.; Simon, D.; Kopf, M.; Otto, M.; Baier, M. Role of interleukin-1 in prion disease-associated astrocyte activation. Am. J. Pathol., 2004, 165, 671-678.
79. Marcos-Carcavilla, A.; Calvo, J.H.; Gonzalez, C.; Moazami-Goudarzi, K.; Laurent, P.; Bertaud, M.; Hayes, H.; Beattie, A.E.; Serrano, C.; Lyahyai, J.; Martin-Burriel, I.; Alves, E.; Zaragoza, P.; Badiola, J.J.; Serrano, M. IL-1 family members as candidate genes modulating scrapie susceptibility in sheep: localization, partial characterization, and expression. Mamm. Genome., 2007, 18, 53-63.
80. Mosser, D.M.; Zhang, X. Interleukin-10: new perspectives on an old cytokine. Immunol. Rev., 2008, 226, 205-218.
81. Thackray, A.M.; McKenzie, A.N.; Klein, M.A.; Lauder, A.; Bujdoso, R. Accelerated prion disease in the absence of interleukin-10. J. Virol., 2004, 78, 13697-13707.
82. Kielian, T. Microglia and chemokines in infectious diseases of the nervous system: views and reviews. Front. Biosci., 2004, 9, 732-750.
83. Tsunoda, I.; Lane, T.E.; Blackett, J.; Fujinami, R.S. Distinct roles for IP-10/CXCL10 in three animal models, Theiler's virus infection, EAE, and MHV infection, for multiple sclerosis: implication of differing roles for IP-10. Mult. Scler., 2004, 10, 26-34.
84. Szczucinski, A.; Losy, J. Chemokines and chemokine receptors in multiple sclerosis. Potential targets for new therapies. Acta Neurol. Scand., 2007, 115, 137-146.
85. Eikelenboom, P.; Veerhuis, R.; Scheper, W.; Rozemuller, A.J.; van Gool, W.A.; Hoozemans, J.J. The significance of neuroinflammation in understanding Alzheimer's disease. J. Neural Transm., 2006, 113, 1685-1695.
86. Wyss-Coray, T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat. Med., 2006, 12, 1005-1015.
87. Wang, Q.; Tang, X.N.; Yenari, M.A. The inflammatory response in stroke. J. Neuroimmunol., 2007, 184, 53-68.
88. Ransohoff, R.M.; Liu, L.; Cardona, A.E. Chemokines and chemokine receptors: multipurpose players in neuroinflammation. Int. Rev. Neurobiol., 2007, 82, 187-204.
89. Savarin-Vuaillat, C.; Ransohoff, R.M. Chemokines and chemokine receptors in neurological disease: raise, retain, or reduce? Neurotherapeutics, 2007, 4, 590-601.
90. Baker, C.A.; Martin, D.; Manuelidis, L. Microglia from Creutzfeldt-Jakob disease-infected brains are infectious and show specific mRNA activation profiles. J. Virol., 2002, 76, 10905-10913.
91. Baker, C.A.; Manuelidis, L. Unique inflammatory RNA profiles of microglia in Creutzfeldt-Jakob disease. Proc. Natl. Acad. Sci. USA, 2003, 100, 675-679.
92. Lu, Z.Y.; Baker, C.A.; Manuelidis, L. New molecular markers of early and progressive CJD brain infection. J. Cell Biochem., 2004, 93, 644-652.
93. Felton, L.M.; Cunningham, C.; Rankine, E.L.; Waters, S.; Boche, D.; Perry, V.H. MCP-1 and murine prion disease: separation of early behavioural dysfunction from overt clinical disease. Neurobiol. Dis., 2005, 20, 283-295.
94. Priller, J.; Prinz, M.; Heikenwalder, M.; Zeller, N.; Schwarz, P.; Heppner, F.L.; Aguzzi, A. Early and rapid engraftment of bone marrow-derived microglia in scrapie. J. Neurosci., 2006, 26, 11753-11762.
95. Yamamoto, M.; Horiba, M.; Buescher, J.L.; Huang, D.; Gendelman, H.E.; Ransohoff, R.M.; Ikezu, T. Overexpression of monocyte chemotactic protein-1/CCL2 in beta-amyloid precursor protein transgenic mice show accelerated diffuse beta-amyloid deposition. Am. J. Pathol., 2005, 166, 1475-1485.
96. El Khoury, J.; Toft, M.; Hickman, S.E.; Means, T.K.; Terada, K.; Geula, C.; Luster, A.D. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat. Med., 2007, 13, 432-438.
97. Lee, H.P.; Jun, Y.C.; Choi, J.K.; Kim, J.I.; Carp, R.I.; Kim, Y.S. The expression of RANTES and chemokine receptors in the brains of scrapie-infected mice. J. Neuroimmunol., 2005, 158, 26-33.
98. LaCasse, R.A.; Striebel, J.F.; Favara, C.; Kercher, L.; Chesebro, B. Role of Erk1/2 activation in prion disease pathogenesis: absence of CCR1 leads to increased Erk1/2 activation and accelerated disease progression. J. Neuroimmunol., 2008, 196, 16-26.
99. Flynn, G.; Maru, S.; Loughlin, J.; Romero, I.A.; Male, D. Regulation of chemokine receptor expression in human microglia and astrocytes. J. Neuroimmunol., 2003, 136, 84-93.
100. Biber, K.; Dijkstra, I.; Trebst, C.; De Groot, C.J.; Ransohoff, R.M.; Boddeke, H.W. Functional expression of CXCR3 in cultured mouse and human astrocytes and microglia. Neuroscience, 2002, 112, 487-497.
101. Xia, M.Q.; Bacskai, B.J.; Knowles, R.B.; Qin, S.X.; Hyman, B.T. Expression of the chemokine receptor CXCR3 on neurons and the elevated expression of its ligand IP-10 in reactive astrocytes: in vitro ERK1/2 activation and role in Alzheimer's disease. J. Neuroimmunol., 2000, 108, 227-235.
102. Omari, K.M.; John, G.R.; Sealfon, S.C.; Raine, C.S. CXC chemokine receptors on human oligodendrocytes: implications for multiple sclerosis. Brain, 2005, 128, 1003-1015.
103. Horuk, R. Chemokine receptors. Cytokine Growth Factor Rev., 2001, 12, 313-335.
104. Jenh, C.H.; Cox, M.A.; Hipkin, W.; Lu, T.; Pugliese-Sivo, C.; Gonsiorek, W.; Chou, C.C.; Narula, S.K.; Zavodny, P.J. Human B cell-attracting chemokine 1 (BCA-1; CXCL13) is an agonist for the human CXCR3 receptor. Cytokine, 2001, 15, 113-121.
105. Rappert, A.; Biber, K.; Nolte, C.; Lipp, M.; Schubel, A.; Lu, B.; Gerard, N.P.; Gerard, C.; Boddeke, H.W.; Kettenmann, H. Secondary lymphoid tissue chemokine (CCL21) activates CXCR3 to trigger a Cl- current and chemotaxis in murine microglia. J. Immunol., 2002, 168, 3221-3226.
106. Biber, K.; Sauter, A.; Brouwer, N.; Copray, S.C.; Boddeke, H.W. Ischemia-induced neuronal expression of the microglia attracting chemokine Secondary Lymphoid-tissue Chemokine (SLC). Glia, 2001, 34, 121-133.
107. Rappert, A.; Bechmann, I.; Pivneva, T.; Mahlo, J.; Biber, K.; Nolte, C.; Kovac, A.D.; Gerard, C.; Boddeke, H.W.; Nitsch, R.; Kettenmann, H. CXCR3-dependent microglial recruitment is essential for dendrite loss after brain lesion. J. Neurosci., 2004, 24, 8500-8509.
108. Riemer, C.; Schultz, J.; Burwinkel, M.; Schwarz, A.; Mok, S.W.; Gultner, S.; Bamme, T.; Norley, S.; van Landeghem, F.; Lu, B.; Gerard, C.; Baier, M. Accelerated prion replication but prolonged survival times of prion-infected CXCR3-/ - mice. J. Virol., 2008, 82, 12464-12471.
109. Carp, R.I.; Callahan, S.M. In vitro interaction of scrapie agent and mouse peritoneal macrophages. Intervirology, 1981, 16, 8-13.
110. Carp, R.I.; Callahan, S.M. Effect of mouse peritoneal macrophages on scrapie infectivity during extended in vitro incubation. Intervirology, 1982, 17, 201-207.
111. Beringue, V.; Demoy, M.; Lasmezas, C.I.; Gouritin, B.; Weingarten, C.; Deslys, J.P.; Andreux, J.P.; Couvreur, P.; Dormont, D. Role of spleen macrophages in the clearance of scrapie agent early in pathogenesis. J. Pathol., 2000, 190, 495-502.
112. Maignien, T.; Shakweh, M.; Calvo, P.; Marce, D.; Sales, N.; Fattal, E.; Deslys, J.P.; Couvreur, P.; Lasmezas, C.I. Role of gut macrophages in mice orally contaminated with scrapie or BSE. Int. J. Pharm., 2005, 298, 293-304.
113. Falsig, J.; Julius, C.; Margalith, I.; Schwarz, P.; Heppner, F.L.; Aguzzi, A. A versatile prion replication assay in organotypic brain slices. Nat. Neurosci., 2008, 11, 109-117.
114. Brown, D.R.; Schmidt, B.; Kretzschmar, H.A. Role of microglia and host prion protein in neurotoxicity of a prion protein fragment. Nature, 1996, 380, 345-347.
115. Brown, D.R. Prion protein peptide neurotoxicity can be mediated by astrocytes. J. Neurochem., 1999, 73, 1105-1113.
116. Eikelenboom, P.; Bate, C.; Van Gool, W.A.; Hoozemans, J.J.; Rozemuller, J.M.; Veerhuis, R.; Williams, A. Neuroinflammation in Alzheimer's disease and prion disease. Glia, 2002, 40, 232-239.
117. Forloni, G.; Del Bo, R.; Angeretti, N.; Chiesa, R.; Smiroldo, S.; Doni, R.; Ghibaudi, E.; Salmona, M.; Porro, M.; Verga, L.; Giaccone, G.; Bugiani, O.; Tagliavini, F. A neurotoxic prion protein fragment induces rat astroglial proliferation and hypertrophy. Eur. J. Neurosci., 1994, 6, 1415-1422.
118. Florio, T.; Grimaldi, M.; Scorziello, A.; Salmona, M.; Bugiani, O.; Tagliavini, F.; Forloni, G.; Schettini, G. Intracellular calcium rise through L-type calcium channels, as molecular mechanism for prion protein fragment 106-126-induced astroglial proliferation. Biochem. Biophys. Res. Commun., 1996, 228, 397-405.
119. Fioriti, L.; Angeretti, N.; Colombo, L.; De Luigi, A.; Colombo, A.; Manzoni, C.; Morbin, M.; Tagliavini, F.; Salmona, M.; Chiesa, R.; Forloni, G. Neurotoxic and gliotrophic activity of a synthetic peptide homologous to Gerstmann-Straussler-Scheinker disease amyloid protein. J. Neurosci., 2007, 27, 1576-1583.
120. Ye, X.; Scallet, A.C.; Kascsak, R.J.; Carp, R.I. Astrocytosis and amyloid deposition in scrapie-infected hamsters. Brain Res., 1998, 809, 277-287.
121. Brazier, M.W.; Wall, V.A.; Brazier, B.W.; Masters, C.L.; Collins, S.J. Therapeutic interventions ameliorating prion disease. Expert Rev. Anti Infect. Ther., 2009, 7, 83-105.
122. Burwinkel, M.; Schwarz, A.; Riemer, C.; Schultz, J.; van Landeghem, F.; Baier, M. Rapid disease development in scrapieinfected mice deficient for CD40 ligand. EMBO Rep., 2004, 5, 527-531.
123. Streit, W.J. Microglia and neuroprotection: implications for Alzheimer's disease. Brain Res. Brain Res. Rev., 2005, 48, 234-239.
124. Bate, C.; Rutherford, S.; Gravenor, M.; Reid, S.; Williams, A. Cyclo-oxygenase inhibitors protect against prion-induced neurotoxicity in vitro. Neuroreport, 2002, 13, 1933-1938.
125. Riemer, C.; Burwinkel, M.; Schwarz, A.; Gultner, S.; Mok, S.W.; Heise, I.; Holtkamp, N.; Baier, M. Evaluation of drugs for treatment of prion infections of the central nervous system. J. Gen. Virol., 2008, 89, 594-597.
126. Martin, B.K.; Szekely, C.; Brandt, J.; Piantadosi, S.; Breitner, J.C.; Craft, S.; Evans, D.; Green, R.; Mullan, M. Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch. Neurol., 2008, 65, 896-905.
127. Vlad, S.C.; Miller, D.R.; Kowall, N.W.; Felson, D.T. Protective effects of NSAIDs on the development of Alzheimer disease. Neurology, 2008, 70, 1672-1677.
128. Menon, V.P.; Sudheer, A.R. Antioxidant and anti-inflammatory properties of curcumin. Adv. Exp. Med. Biol., 2007, 595, 105-125.
129. Yang, F.; Lim, G.P.; Begum, A.N.; Ubeda, O.J.; Simmons, M.R.; Ambegaokar, S.S.; Chen, P.P.; Kayed, R.; Glabe, C.G.; Frautschy, S.A.; Cole, G.M. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J. Biol. Chem., 2005, 280, 5892-5901.
130. Garcia-Alloza, M.; Borrelli, L.A.; Rozkalne, A.; Hyman, B.T.; Bacskai, B.J. Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model. J. Neurochem., 2007, 102, 1095-1104.
131. Caughey, B.; Raymond, L.D.; Raymond, G.J.; Maxson, L.; Silveira, J.; Baron, G.S. Inhibition of protease-resistant prion protein accumulation in vitro by curcumin. J. Virol., 2003, 77, 5499-5502.
132. Lim, G.P.; Chu, T.; Yang, F.; Beech, W.; Frautschy, S.A.; Cole, G.M. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J. Neurosci., 2001, 21, 8370-8377.
133. Gautam, S.C.; Gao, X.; Dulchavsky, S. Immunomodulation by curcumin. Adv. Exp. Med. Biol., 2007, 595, 321-341.
134. Bate, C.; Salmona, M.; Diomede, L.; Williams, A. Squalestatin cures prion-infected neurons and protects against prion neurotoxicity. J. Biol. Chem., 2004, 279, 14983-14990.
135. Taraboulos, A.; Scott, M.; Semenov, A.; Avrahami, D.; Laszlo, L.; Prusiner, S.B. Cholesterol depletion and modification of COOH-terminal targeting sequence of the prion protein inhibit formation of the scrapie isoform. J. Cell Biol., 1995, 129, 121-132.
136. Weitz-Schmidt, G. Welzenbach, K.; Brinkmann, V.; Kamata, T.; Kallen, J.; Bruns, C.; Cottens, S.; Takada, Y.; Hommel, U. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat. Med., 2001, 7, 687-692.
137. Weitz-Schmidt, G. Statins as anti-inflammatory agents. Trends Pharmacol. Sci., 2002, 23, 482-486.
138. Youssef, S.; Stuve, O.; Patarroyo, J.C.; Ruiz, P.J.; Radosevich, J.L.; Hur, E.M.; Bravo, M.; Mitchell, D.J.; Sobel, R.A.; Steinman, L.; Zamvil, S.S. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature, 2002, 420, 78-84.
139. Mok, S.W.; Thelen, K.M.; Riemer, C.; Bamme, T.; Gultner, S. Lutjohann, D.; Baier, M. Simvastatin prolongs survival times in prion infections of the central nervous system. Biochem. Biophys. Res. Commun., 2006, 348, 697-702.
140. Haviv, Y.; Avrahami, D.; Ovadia, H.; Ben-Hur, T.; Gabizon, R.; Sharon, R. Induced neuroprotection independently from PrPSc accumulation in a mouse model for prion disease treated with simvastatin. Arch. Neurol., 2008, 65, 762-775.
141. Kempster, S.; Bate, C.; Williams, A. Simvastatin treatment prolongs the survival of scrapie-infected mice. Neuroreport, 2007, 18, 479-482.
142. Vetrugno, V.; Di Bari, M.A.; Nonno, R.; Puopolo, M.; D'Agostino, C.; Pirisinu, L.; Pocchiari, M.; Agrimi, U. Oral pravastatin prolongs survival time of scrapie-infected mice. J. Gen. Virol., 2009, 90, 1775-1780.
143. Quiniou, C.; Kooli, E.; Joyal, J.S.; Sapieha, P.; Sennlaub, F.; Lahaie, I.; Shao, Z.; Hou, X.; Hardy, P.; Lubell, W.; Chemtob, S. Interleukin-1 and ischemic brain injury in the newborn: development of a small molecule inhibitor of IL-1 receptor. Semin. Perinatol., 2008, 32, 325-333.
144. Adamson, P. Therapeutic strategies targeting interleukin-1 in vascular inflammation. Drug Discov. Today Ther. Strategy, 2006, 3, 367-373.
145. Suzuki, N.; Suzuki, S.; Duncan, G.S.; Millar, D.G.; Wada, T.; Mirtsos, C.; Takada, H.; Wakeham, A.; Itie, A.; Li, S.; Penninger, J.M.; Wesche, H.; Ohashi, P.S.; Mak, T.W.; Yeh, W.C. Severe impairment of interleukin-1 and Toll-like receptor signalling in mice lacking IRAK-4. Nature, 2002, 416, 750-756.
146. Wijtmans, M.; Verzijl, D.; Leurs, R.; de Esch, I.J.; Smit, M.J. Towards small-molecule CXCR3 ligands with clinical potential. ChemMedChem., 2008, 3, 861-872.
147. Kordek, R.; Nerurkar, V.R.; Liberski, P.P.; Isaacson, S.; Yanagihara, R.; Gajdusek, D.C. Heightened expression of tumor necrosis factor alpha, interleukin 1 alpha, and glial fibrillary acidic protein in experimental Creutzfeldt-Jakob disease in mice. Proc. Natl. Acad. Sci. USA, 1996, 93, 9754-9758.
148. Stoeck, K.; Bodemer, M.; Ciesielczyk, B.; Meissner, B.; Bartl, M.; Heinemann, U.; Zerr, I. Interleukin 4 and interleukin 10 levels are elevated in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Arch. Neurol., 2005, 62, 1591-1594.
149. Stoeck, K.; Bodemer, M.; Zerr, I. Pro- and anti-inflammatory cytokines in the CSF of patients with Creutzfeldt-Jakob disease. J. Neuroimmunol., 2006, 172, 175-181.
150. Cunningham, C.; Boche, D.; Perry, V.H. Transforming growth factor beta1, the dominant cytokine in murine prion disease: influence on inflammatory cytokine synthesis and alteration of vascular extracellular matrix. Neuropathol. Appl. Neurobiol., 2002, 28, 107-119.
151. Lee, Y.J.; Jin, J.K.; Jeong, B.H.; Carp, R.I.; Kim, Y.S. Increased expression of glial cell line-derived neurotrophic factor (GDNF) in the brains of scrapie-infected mice. Neurosci. Lett., 2006, 410, 178-182.
152. Xiang, W.; Hummel, M.; Mitteregger, G.; Pace, C.; Windl, O.; Mansmann, U.; Kretzschmar, H.A. Transcriptome analysis reveals altered cholesterol metabolism during the neurodegeneration in mouse scrapie model. J. Neurochem., 2007, 102, 834-847.
153. Marella, M.; Chabry, J. Neurons and astrocytes respond to prion infection by inducing microglia recruitment. J. Neurosci., 2004, 24, 620-627.